R42 Group
VC Fund
Stanford, United States
R42 Group is a VC fund in Stanford focused on Biotechnology and Health Care. R42 Group actively invents and finances deep science ventures. R42 Group will work from the pre-seed inventing stage through to the growth stage.
- Total investments:
- 35
- Last investment:
- Lead investor:
- 29%
- Fund size:
- $5.3M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries R42 Group invests in
Stages R42 Group invests in
Countries R42 Group invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Seed
- $754k–$8M
- Pre-Seed
- $472k–$2M
- Series A
- $4.2M–$40M
Investment Focus
Industry
- Biotechnology 12 (34%)
- Health Care 9 (26%)
- Software 5 (14%)
- Medical 4 (11%)
- Artificial Intelligence 4 (11%)
Stage
- Seed 14 (40%)
- Pre-Seed 5 (14%)
- Series A 4 (11%)
- Venture - Series Unknown 3 (9%)
- Series C 1 (3%)
Country
- United Kingdom 13 (37%)
- United States 7 (20%)
- Austria 1 (3%)
- Switzerland 1 (3%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Anastasiya Giarletta
Principal
|
Principal | Total investments: 2 | Find email | |
Indu Navar
Limited Partner
|
Limited Partner | Total investments: 0 | Find email | |
Ronjon Nag
Founder, MD & President
|
Founder, MD & President | Total investments: 14 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Stamp Free operates as a digital postage stamp company that provides postage solutions. The company provides an app that allows personal and business customers to buy stamps or digital postage directly on their mobile phones and then post their letters or parcels in the normal way. | $1.4M / Venture - Series Unknown / May 19, 2026 | ||
| xwatts is an intelligent energy management system that helps commercial buildings reduce costs and emissions. | $2.2M / Seed / Feb 10, 2026 | ||
| Cordance Medical is a medical device company that develops radical therapy for a variety of CNS pathology, including primary and metastatic cancer, Alzheimer's, and Parkinson's diseases. | $8M / Seed / Nov 24, 2025 | ||
| Soopra is a platform that allows experts to create AI personas to interact with their audiences 24/7, providing a new, scalable way to monetize their knowledge. | $1M / Pre-Seed / May 14, 2025 | ||
| Abselion is the biological sensor for rapid and cost-effective detection of biological substances like proteins, DNA, or small molecules. | $8.4M / Series A / Dec 04, 2024 | ||
| Healx is a mission-driven technology company pioneering the next wave of drug discovery in order to bring novel, effective treatments to rare disease patients around the world. There are 7,000 known rare diseases that affect 400 million people across the globe, but only 5% of those conditions have an approved treatment. By combining frontier AItechnology with deep drug discovery and development expertise, Healx can accelerate the pace, increase the scale and improve the chance of success of rare disease treatment development in order to meet this huge unmet need and have unprecedented patient impact. Founded in Cambridge, UK, in 2014 by Dr Tim Guilliams (a Biochemical Engineer and tech entrepreneur) and Dr David Brown (co-inventor of Viagra and former Global Head of Drug Discovery at Roche), Healx has raised $70 million to date. For more information, visit www.healx.io. | $47M / Series C / Aug 01, 2024 | ||
| xwatts is an intelligent energy management system that helps commercial buildings reduce costs and emissions. | $1.8M / Pre-Seed / Jul 18, 2024 | ||
| Rubedo Life Sciences mission is to treat age-related diseases to extend health-span targeting senescence and stem cells. | $40M / Series A / Apr 22, 2024 | ||
| Developing a new generation of senotherapeutic interventions to target the diseases and aesthetic signs of ageing. | $4.8M / Mar 18, 2024 | ||
| Developing a new generation of senotherapeutic interventions to target the diseases and aesthetic signs of ageing. | $4.7M / Seed / Mar 18, 2024 | ||
| See all 35 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does R42 Group invest in?
R42 Group invests primarily in Biotechnology, Health Care and Software startups, most often at Seed and Pre-Seed stage. Most of the 35 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is R42 Group's check size?
R42 Group typically joins rounds of $754k–$8M at Seed, $472k–$2M at Pre-Seed and $4.2M–$40M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds R42 Group participates in.
How do I contact R42 Group?
Public channels for R42 Group include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at R42 Group?
The team at R42 Group includes Anastasiya Giarletta (Principal), Indu Navar (Limited Partner) and Ronjon Nag (Founder, MD & President). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
